Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

NCT07355335 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

KMT2A-rearranged
NPM1-mutant Refractory or Relapsed AML

Interventions

DRUG: Ziftomenib
DRUG: Mezigdomide

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]